AKTX · Akari Therapeutics Plc
$8.46
-0.24 (-2.70%)
At close · Jul 27
Going-concern doubt
— flagged May 19, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern for at least a one-year period following the issuance of these condensed consolidated financial statements.”View the 10-Q filed May 19, 2026
Market Cap
$14.81M
Shares
1.75M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Abizer Gaslightwala | CEO | $1,663,603 |
| Torsten Hombeck | CFO | $621,955 |
| Samir R. Patel | CEO | $324,985 |
| Kameel Farag | CFO | $117,435 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Rachelle Jacques | CEO | $1,401,173 |
| Wendy DiCicco | CFO | $860,844 |
| Samir R. Patel | CEO | $435,767 |
| Torsten Hombeck | CFO | $12,500 |
| Kameel Farag | CFO | — |
| Abizer Gaslightwala | CEO | — |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Rachelle Jacques | CEO | $1,560,141 |
| Wendy DiCicco | CFO | $277,664 |
| Torsten Hombeck | CFO | $167,506 |
| Samir R. Patel | CEO | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Rachelle Jacques | CEO | $3,602,599 |
| Torsten Hombeck | CFO | $448,745 |